| Literature DB >> 30201946 |
Wei Zhang1, Chang Liu1, Yifei Tan1, Lingcan Tan2, Li Jiang1, Jian Yang1, Jiayin Yang1, Lunan Yan1, Tianfu Wen1.
Abstract
BACKGROUND Albumin-Bilirubin (ALBI) grade has been evaluated as an objective method to assess liver function and predict postoperative complications, particularly after hepatectomy in patients with hepatocellular carcinoma (HCC). However, ALBI grade was rarely used in evaluation in living donor liver transplantation (LDLT). MATERIAL AND METHODS Between March 2005 and November 2015, 272 consecutive patients undergoing right-lobe LDLT were enrolled in this study. According to the ALBI score used to evaluate recipients preoperatively, those patients were divided into 3 grades (I, II, and III). Demographic findings and the post-operative complication rates were collected and compared among groups. RESULTS The proportions of massive blood cell transfusions were different among those 3 grades (p<0.05). The patients in grade III had a higher risk of bacterial pneumonia and early allograft dysfunction (EAD) compared to grade I (p=0.029 and p=0.038, respectively) and grade II (p=0.006 and p=0.007, respectively). The area under the receiver operating characteristic curve of ALBI, Child-Pugh, and MELD for predicting 30-day mortality were 0.702 (95% CI: 0.644-0.756), 0.669 (95% CI: 0.580-0.697, p=0.510, versus ALBI grade), and 0.540 (95% CI: 0.580-0.697, p=0.144, versus ALBI grade), respectively. CONCLUSIONS ALBI grade was a good index for predicting post-operative complications and had a predictive ability similar to those of the Child-Pugh classification and MELD score.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30201946 PMCID: PMC6248303 DOI: 10.12659/AOT.910824
Source DB: PubMed Journal: Ann Transplant ISSN: 1425-9524 Impact factor: 1.530
Preoperative and surgical characteristics of recipients in different ALBI group.
| ALBI-I | ALBI-II | ALBI-III | P value | P value | P value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Recipient age (year) | 41.4 | (±8.9) | 42.9 | (±8.8) | 42.0 | (±8.8) | 0.311 | 0.451 | 0.708 |
| Donor age (year) | 35.8 | (±8.1) | 36.7 | (±10.4) | 35.7 | (±10.9) | 0.561 | 0.507 | 0.947 |
| Recipient Male (%) | 41 | (85.4) | 114 | (83.8) | 75 | (85.2) | 0.795 | 0.777 | 0.976 |
| Recipient BMI (kg/m2) | 22.9 | (±2.5) | 22.4 | (±3.1) | 22.54 | (±3.40) | 0.277 | 0.706 | 0.465 |
| Pre-transplant creatinine (umol/L) | 80 | (±25) | 78 | (±27) | 99 | (±64) | 0.585 | 0.004 | 0.016 |
| Pre-transplant bilirubin (umol/L) | 18 | (±11) | 61 | (±107) | 224 | (±215) | <0.001 | <0.001 | <0.001 |
| Pre-transplant INR | 1.11 | (±0.21) | 1.34 | (±0.36) | 2.32 | (±1.97) | <0.001 | <0.001 | <0.001 |
| MELD at Transplant | 7.5 | (6.1–9.3) | 11.5 | (8.8–14.8) | 17.6 | (15.2–23.1) | <0.001 | <0.001 | <0.001 |
| Child-Pugh stage | |||||||||
| A | 18 | (37.5) | 40 | (29.4) | 4 | (4.5) | 0.300 | <0.001 | <0.001 |
| B | 29 | (60.4) | 83 | (61.0) | 28 | (31.8) | 0.940 | <0.001 | 0.001 |
| C | 1 | (2.1) | 13 | (9.6) | 56 | (63.7) | 0.119 | <0.001 | <0.001 |
| GRWR | 0.88 | (±0.18) | 0.96 | (±0.22) | 0.96 | (±0.21) | 0.009 | 0.968 | 0.014 |
| Cold ischemia time (min) | 98 | (20–201) | 90 | (20–191) | 88 | (21–188) | 0.681 | 0.933 | 0.695 |
| Duration of anhepatic phase (min) | 77 | (63–95) | 89 | (67–110) | 92 | (64–109) | 0.042 | 0.831 | 0.057 |
| Estimated blood loss (mL) | 1183 | (±1273) | 1538 | (±2045) | 2045 | (±2810) | 0.165 | 0.146 | 0.015 |
| Massive blood cell transfusion (%) | 16 | (33.3) | 79 | (58.1) | 65 | (73.9) | 0.003 | 0.016 | <0.001 |
| Etiology of liver disease | |||||||||
| HBV infection (%) | 39 | (81.3) | 105 | (77.2) | 60 | (68.2) | 0.559 | 0.134 | 0.102 |
| HBV related cirrhosis without tumor (%) | 4 | (8.3) | 32 | (23.5) | 31 | (35.2) | 0.021 | 0.057 | 0.001 |
| HCC (%) | 43 | (89.6) | 82 | (60.3) | 20 | (22.7) | <0.001 | <0.001 | <0.001 |
| Fulminant hepatic failure (%) | 0 | (0) | 4 | (2.9) | 19 | (21.6) | 0.574 | <0.001 | <0.001 |
Means (SD);
Median (IQR).
BMI – body mass index; MELD – model for end-stage liver disease; GRWR – graft- to-recipient weight ratio; HCC – hepatocellular carcinoma.
Perioperative complications of recipients in different ALBI group.
| ALBI-I | ALBI-II | ALBI-III | P value | P value | P value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-transplantation complications | |||||||||
| Encephalopathy (%) | 0 | (0) | 3 | (2.2) | 17 | (19.3) | 0.569 | <0.001 | 0.001 |
| GI bleeding (%) | 1 | (2.1) | 14 | (10.3) | 5 | (5.7) | 0.121 | 0.226 | 0.589 |
| Peritonitis (%) | 1 | (2.1) | 3 | (2.2) | 3 | (3.4) | 0.960 | 0.904 | 0.662 |
| Renal insuffienciency (%) | 1 | (2.1) | 1 | (0.7) | 4 | (4.5) | 0.455 | 0.155 | 0.801 |
| Uncontrolled ascites (%) | 1 | (2.1) | 12 | (8.8) | 18 | (20.5) | 0.189 | 0.013 | 0.007 |
| Early post-operative complications (%) | |||||||||
| Post-operative bleeding (%) | 2 | (4.2) | 3 | (2.2) | 9 | (10.2) | 0.840 | 0.021 | 0.363 |
| Arterial thrombosis (%) | 0 | (0) | 4 | (2.9) | 2 | (2.3) | 0.574 | 0.762 | 0.540 |
| Portal vein thrombosis (%) | 0 | (0) | 3 | (2.2) | 1 | (1.1) | 0.569 | 0.941 | 0.459 |
| Biliary leakage (%) | 0 | (0) | 4 | (2.9) | 3 | (3.4) | 0.574 | 0.844 | 0.552 |
| Intra-abdominal collection (%) | 8 | (16.7) | 23 | (16.9) | 18 | (20.5) | 0.969 | 0.503 | 0.591 |
| Bacterial pneumonia (%) | 1 | (2.1) | 5 | (3.7) | 12 | (13.6) | 0.951 | 0.006 | 0.029 |
| Pleural effusion (%) | 9 | (18.8) | 24 | (17.6) | 17 | (19.3) | 0.864 | 0.752 | 0.936 |
| Renal failure (%) | 0 | (0) | 3 | (2.2) | 4 | (4.5) | 0.569 | 0.555 | 0.297 |
| EAD (%) | 3 | (6.3) | 12 | (8.8) | 19 | (21.6) | 0.800 | 0.007 | 0.038 |
| GRWR <0.8% | 16 | (33.3) | 37 | (27.2) | 19 | (21.6) | 0.420 | 0.343 | 0.134 |
| SFSD (/GRWR <0.8%), (%) | 2 | (12.5) | 7 | (18.9) | 6 | (31.6) | 0.863 | 0.288 | 0.244 |
| SFSD (%) | 2 | (4.2) | 7 | (5.1) | 6 | (6.8) | 0.787 | 0.601 | 0.805 |
| Late post-operative complications (%) | |||||||||
| Hepatic vein thrombosis (%) | 1 | (2.1) | 2 | (5.1) | 3 | (3.4) | 0.773 | 0.620 | 0.662 |
| Biliary leakage (%) | 0 | (0) | 5 | (3.7) | 3 | (3.4) | 0.329 | 0.916 | 0.552 |
| Biliary stenosis (%) | 1 | (2.1) | 7 | (5.1) | 4 | (4.5) | 0.629 | 0.839 | 0.801 |
| Dindo-Clavien IIIb, IV within 30d (%) | 7 | (14.6) | 16 | (11.8) | 20 | (22.7) | 0.612 | 0.029 | 0.255 |
| 30-day mortality | 1 | (2.1) | 5 | (3.7) | 13 | (14.8) | 0.593 | 0.003 | 0.042 |
| 6-month mortality | 4 | (8.3) | 13 | (9.5) | 20 | (22.7) | 0.801 | 0.007 | 0.035 |
GI – gastrointestinal bleeding; EAD – early allograft dysfunction; SFSD – small-for-size dysfunction.
Figure 1Receiver operating characteristics (ROC) curves for pre-operative albumin-bilirubin (ALBI), MELD, and Child-Pugh in predicting intra-transplant probability of massive blood transfusion in the whole group of living donor liver transplantation patients.
Figure 2Receiver operating characteristics (ROC) curves for pre-operative albumin-bilirubin (ALBI), MELD, and Child-Pugh in predicting postoperative bacterial pneumonia (A) and early allograft dysfunction (B).
Figure 3Receiver operating characteristics (ROC) curves for pre-operative albumin-bilirubin (ALBI), MELD, and Child-Pugh in predicting severe complication rate (A) and 30-day mortality (B).